



Achillion Pharmaceuticals  
 Investor Relations Department  
 300 George St.  
 New Haven, CT 06511  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

<b>NASDAQ: ACHN</b>	
Last Trade:	4.39
Trade Time:	1:29 PM ET Jun 28, 2017
Change:	-0.03 <span style="color:red">↓</span> (-0.701%)
Day Range	4.36 - 4.48
52-Week Range	3.15 - 9.50
Volume	847,405

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Jun 15, 2017*  
[Achillion to Present at the 2017 JMP Securities Life Sciences Conference](#)
- Jun 5, 2017*  
[Achillion to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 4, 2017*  
[Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs](#)
- May 2, 2017*  
[Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference](#)
- Apr 22, 2017*  
[Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178](#)

### Financial Disclosures [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 23, 2017*  
[Annual Report \(10-K\)](#)
- Apr 17, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)